Literature DB >> 27001408

The pharmacokinetics of ampicillin-sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery.

Yuta Yokoyama1,2, Kazuaki Matsumoto1, Kazuro Ikawa2, Erika Watanabe2, Hiroyuki Yamamoto3, Yutaka Imoto3, Norifumi Morikawa2, Yasuo Takeda4.   

Abstract

Background The administration of antibiotic prophylaxis during cardiothoracic surgery can reduce the rate of surgical site infections. Trials of cardiothoracic antibiotic prophylaxis have found it to be beneficial in preventing postoperative wound infections. Objective To determine the more appropriate timing of repeated doses of ampicillin-sulbactam to maintain adequate antibiotic concentrations during cardiovascular surgery in anuric patients. Method Five adult anuric dialysis patients who received ampicillin-sulbactam during cardiovascular surgery at Kagoshima University Hospital, the total plasma concentrations of ampicillin and sulbactam were monitored after ampicillin (1 g)-sulbactam (0.5 g) administration. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin and sulbactam. Results The mean values for the volume of distribution, total clearance, elimination rate constant and the elimination half-life for ampicillin were 8.9 ± 2.4 L, 1.69 ± 0.93 L/h, 0.180 ± 0.059 h(-1) and 4.23 ± 1.48 h, respectively. The pharmacokinetic parameters were similar to those of sulbactam. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered at 8, 12 and 24 h intervals, the predicted free trough plasma concentrations of ampicillin were 28.72, 12.06 and 1.25 μg/mL, respectively. Conclusion We suggest that ampicillin (1 g)-sulbactam (0.5 g) should be intravenously administered every 12 h in order to maintain a free ampicillin concentration of more than 12 μg/mL in anuric patients during cardiovascular surgery.

Entities:  

Keywords:  Ampicillin–sulbactam; Anuria; Cardiovascular surgery; Prophylaxis

Mesh:

Substances:

Year:  2016        PMID: 27001408     DOI: 10.1007/s11096-016-0286-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  9 in total

1.  Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery.

Authors:  Yuta Yokoyama; Kazuaki Matsumoto; Hiroyuki Yamamoto; Yoshifumi Iguro; Yutaka Imoto; Kazuro Ikawa; Norifumi Morikawa; Shiro Ishida; Yoshiro Okano; Erika Watanabe; Yoshihiro Shimodozono; Katsushi Yamada; Yasuo Takeda
Journal:  J Infect Chemother       Date:  2012-05-30       Impact factor: 2.211

2.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 3.  Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

Authors:  Robin L Trotman; John C Williamson; D Matthew Shoemaker; William L Salzer
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

Review 4.  Postoperative surgical site infections in cardiac surgery--an overview of preventive measures.

Authors:  Bengt Gårdlund
Journal:  APMIS       Date:  2007-09       Impact factor: 3.205

5.  Differences in risk factors associated with surgical site infections following two types of cardiac surgery in Japanese patients.

Authors:  K Morikane; H Honda; T Yamagishi; S Suzuki
Journal:  J Hosp Infect       Date:  2015-01-07       Impact factor: 3.926

6.  Studies on protein binding of cefazolin and other antibiotics.

Authors:  T Shimizu
Journal:  Jpn J Antibiot       Date:  1974-06

7.  Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan.

Authors:  Yoshio Takesue; Akira Watanabe; Hideaki Hanaki; Shinya Kusachi; Tetsuro Matsumoto; Aikichi Iwamoto; Kyoichi Totsuka; Keisuke Sunakawa; Morimasa Yagisawa; Junko Sato; Toyoko Oguri; Kunio Nakanishi; Yoshinobu Sumiyama; Yuko Kitagawa; Go Wakabayashi; Isamu Koyama; Katsuhiko Yanaga; Toshiro Konishi; Ryoji Fukushima; Shiko Seki; Shun Imai; Tsunehiro Shintani; Hiroki Tsukada; Kazuhiro Tsukada; Kenji Omura; Hiroshige Mikamo; Hiromitsu Takeyama; Masato Kusunoki; Shoji Kubo; Junzo Shimizu; Toshihiro Hirai; Hiroki Ohge; Akio Kadowaki; Kohji Okamoto; Katsunori Yanagihara
Journal:  J Infect Chemother       Date:  2012-11-10       Impact factor: 2.211

8.  Gram-negative rod bacteremia after cardiovascular surgery: Clinical features and prognostic factors.

Authors:  Sayaka Tago; Yuji Hirai; Yusuke Ainoda; Takahiro Fujita; Ken Kikuchi
Journal:  J Microbiol Immunol Infect       Date:  2015-08-04       Impact factor: 4.399

9.  Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.

Authors:  Elena Soto; Satoshi Shoji; Chieko Muto; Yoshiro Tomono; Scott Marshall
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

  9 in total
  2 in total

1.  Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.

Authors:  Abdul Haseeb; Hani Saleh Faidah; Saleh Alghamdi; Amal F Alotaibi; Mahmoud Essam Elrggal; Ahmad J Mahrous; Safa S Almarzoky Abuhussain; Najla A Obaid; Manal Algethamy; Abdullmoin AlQarni; Asim A Khogeer; Zikria Saleem; Muhammad Shahid Iqbal; Sami S Ashgar; Rozan Mohammad Radwan; Alaa Mutlaq; Nayyra Fatani; Aziz Sheikh
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

Review 2.  Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.

Authors:  András Fodor; Birhan Addisie Abate; Péter Deák; László Fodor; Ervin Gyenge; Michael G Klein; Zsuzsanna Koncz; Josephat Muvevi; László Ötvös; Gyöngyi Székely; Dávid Vozik; László Makrai
Journal:  Pathogens       Date:  2020-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.